Abstract: Slide Presentations |

Thromboprophylaxis With Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Respiratory Failure FREE TO VIEW

Alexander T. Cohen, MD; Alain Leizorovicz, MD; Alexander G. Turpie, MD; Carl-Gustav Olsson, MD; Paul T. Vaitkus, MD; Samuel Z. Goldhaber, MD; The PREVENT Medical Thromboprophylaxis Study Group
Author and Funding Information

Guy’s, King’s & St Tomas’ School of Medicine, London, UK


Chest. 2003;124(4_MeetingAbstracts):132S-c-133S. doi:10.1378/chest.124.4.1365
Text Size: A A A
Published online


PURPOSE:  Venous thromboembolism (VTE) is a major cause of morbidity and mortality in hospitalized patients. A large international study in acutely ill medical patients assessed the efficacy of the low-molecular-weight heparin dalteparin for prevention of clinically important VTE. We undertook a subanalysis of the study to assess the benefit of thromboprophylaxis in the patients with respiratory failure.

METHODS:  PREVENT was a randomized, double-blind, placebo-controlled trial in hospitalized medical patients at moderately high risk of VTE. Patients received dalteparin (5000 IU QD) or placebo, for 14 days. The primary endpoint was clinically important VTE, defined as objectively verified symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), sudden death, and objectively verified asymptomatic proximal DVT. Compression ultrasound was performed in all patients who had not reached an endpoint by day 21.

RESULTS:  3706 patients were enrolled at 219 centers in 26 countries. The incidence of the composite primary outcome was 2.77% in the dalteparin group and 4.96% in the placebo group, a risk reduction of 45% (95% CI, 20%-62%) [P=0.0015]. Major bleeding occurred in 12 patients, 9 (0.49%) receiving dalteparin and 3 (0.16%) placebo (n.s.) Among the 877 patients admitted with acute respiratory failure not requiring ventilatory support, the primary endpoint incidence was 3.62% (16/442) in the dalteparin group and 5.06% (22/435) in the placebo group, a 28% risk reduction (95% CI, −34% to 62%). In the 947 patients with acute or chronic respiratory failure treated with dalteparin vs placebo the incidence was 3.36% vs 5.10% respectively, a risk reduction of 34% (95% CI, −23% to 65%).CONCLUSIONS: Dalteparin 5000 IU daily reduces clinically important VTE in acutely ill medical patients, including those with respiratory failure, with a low risk of bleeding.

CLINICAL IMPLICATIONS:  More widespread, routine thromboprophylaxis of medically ill patients should reduce the incidence of clinically important VTE and improve outcomes.

DISCLOSURE:  A.T. Cohen, Pharmacia, Grant monies,, Discussion of product research or unlabeled uses of product; Guy’s, King’s and St Thomas’ School of Medicine, University monies. Grant in respect of Steering Committee Consultancy

Wednesday, October 29, 2003

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543